FDA Approvals, News & UpdatesLeukemia

Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation

In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
June 2019 Vol 5 No 3

In May 2019, the FDA approved Tibsovo (ivosidenib; from Agios) for the treatment of patients aged 75 or older with newly diagnosed acute myeloid leukemia (AML) and a susceptible IDH1 mutation, or for patients with AML who have comorbidities (other conditions) that preclude them from using first-line treatment with intensive chemotherapy. Tibsovo should be used based on results of an FDA-approved test that confirm the presence of a susceptible IDH1 mutation. Tibsovo was originally approved by the FDA in 2018 for patients with relapsed or refractory AML and a susceptible IDH1 mutation.

The new approval for Tibsovo as first-line treatment was based on a clinical trial of patients with newly diagnosed AML and an IDH1 mutation, which was detected by the Abbott RealTime IDH1 Assay. All patients were aged 75 or older or had other conditions that prevented them from using intensive ­chemotherapy. All patients received treatment with Tibsovo. After treatment with Tibsovo, 12 (42.9%) of 28 patients achieved complete disease remission or complete remission with partial hematologic recovery, and 7 (41.2%) of the 17 transfusion-dependent patients achieved transfusion independence lasting 8 weeks or longer.

The most common side effects with Tibsovo are diarrhea, fatigue, rash, decreased appetite, elevated white blood cells, nausea, joint and muscle pain, abdominal pain, shortness of breath, and differentiation syndrome.

Recommended For You
“Real World” Assessment of Side Effects and Discontinuation Rates in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Ibrutinib is an orally administered Bruton tyrosine kinase inhibitor used in the treatment of patients with CLL. Because ibrutinib has been prescribed in the United States for several years, researchers sought to learn how the rates of side effects in the “real world” compared with those reported in clinical trials.
Implications of Data Collected in Chronic Lymphocytic Leukemia Patient Registries: Connect CLL and informCLL
When treating patients with CLL, understanding specific details about the disease helps doctors as they choose among available treatments. CLL experts believe that conducting specific blood tests before prescribing each patient’s treatment is critical. Do all doctors who treat patients with CLL also appreciate this need for testing?
Combining Acalabrutinib and Obinutuzumab in Patients with High-Risk Chronic Lymphocytic Leukemia
In a large clinical trial, ibrutinib was shown to be effective in delaying disease progression in patients with early-stage, high-risk CLL who did not yet have symptoms. Researchers are now conducting clinical trials to determine the safety and efficacy of next-generation drugs and combinations in patients with early-stage, high-risk disease.
The Debate Over Early Intervention in Chronic Lymphocytic Leukemia
In the era of targeted treatments for CLL, should patients with early-stage disease be placed on therapy before they experience symptoms? Doctors continue to debate this question while waiting for clinical trial data to evolve.
Last modified: July 15, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.